[CAS NO. 847239-17-2] UVI 3003
PRODUCTS SPECIFICATIONS [847239-17-2]
DESCRIPTION [847239-17-2]
Overview
| MDL | MFCD18086862 |
|---|---|
| Molecular Weight | 436.58 |
| Molecular Formula | C28H36O4 |
| SMILES | CCCCCOC1=C(C2=CC(/C=C/C(O)=O)=CC=C2O)C=C3C(C(C)(CCC3(C)C)C)=C1 |
3 Publications Citing Use of MCE
Summary
UVI 3003 is a highly selective antagonist of retinoid X receptor (RXR) , and inhibits xenopus and human RXRα in Cos7 cells, with IC 50 s of 0.22 and 0.24 μM, respectively.
IC50 & Target
IC50: 0.22 μM (Xenopus RXRα, in Cos7 cells), 0.24 μM (Human RXRα, in Cos7 cells) [1]
In Vitro
UVI3003 inhibits the activity of xenopus and human RXRα, with IC 50 s of 0.22 and 0.24 μM, respectively. UVI3003 fully activates xPPARγ with an EC 50 of 12.6 μM, and is almost completely inactive on hPPARγ and mPPARγ [1] . UVI 3003 (10 μM) does not change the proliferation rate of extraocular muscles (EOM)-derived or LEG-derived EECD34 cells. UVI 3003 causes a 65.4% difference in EECD34 cell fusion and desmin expression [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 229.05 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2905 mL | 11.4527 mL | 22.9053 mL |
| 5 mM | 0.4581 mL | 2.2905 mL | 4.5811 mL |
| 10 mM | 0.2291 mL | 1.1453 mL | 2.2905 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.73 mM); Clear solution
References
- [1] Zhu J, et al. The unexpected teratogenicity of RXR antagonist UVI3003 via activation of PPARγ in Xenopus tropicalis. Toxicol Appl Pharmacol. 2017 Jan 1;314:91-97.
- [2] Hebert SL, et al. Effects of retinoic acid signaling on extraocular muscle myogenic precursor cells in vitro. Exp Cell Res. 2017 Dec 1;361(1):101-111.